


بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات




يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل





**STUDY OF SERUM FETUIN A LEVEL IN PATIENTS WITH
POST HCV LIVER CIRRHOSIS WITH AND WITHOUT
HEPATOCELLULAR CARCINOMA**

*Thesis
Submitted for Partial Fulfillment of M.D. Degree
In Internal Medicine*

By:
Abdalla Mahmoud Tawfik
MBB Ch, Msc.

Supervised by

Prof. Dr. Mansour Nasef Mohamed

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Prof. Dr. Wael Ahmed Yosri

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Dr. Mohamed Lotfy Soliman

*Assistant Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Dr. Khalid Amr Zaki

*Assistant Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
AinShamsUniversity
2019**



وَقُلْ اَعْمَلُوا فَسَيَرَى اللّٰهُ
عَمَلَكُمْ وَرَسُولُهُ وَالْمُؤْمِنُونَ

سورة التوبة (الآية ١٠٥)



صَلَّى
الْعِظِيمِ





Acknowledgement

First, thanks are all due to Allah for Blessing this work until it has reached its end, as a part of his generous help throughout our life.

My profound thanks and deep appreciation to Prof. Dr. Mansour Nasef Mohamed, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain Shams University for his great support and advice, his valuable remarks that gave me the confidence and encouragement to fulfill this work.

I am deeply grateful to Prof. Dr. Wael Ahmed Yosri, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain Shams University for adding a lot to this work by his experience and for his keen supervision.

I am also thankful to Dr. Mohamed Lotfy Soliman, Assistant Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain Shams University, for his invaluable help, fruitful advice, continuous support offered to me and guidance step by step till this essay finished.

I would like to direct my special thanks to Dr. Khalid Amr Zaki, Assistant Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain Shams University, for his valuable supervision, co-operation and direction that extended throughout this work.

I am extremely sincere to myfamily who stood beside me throughout this work giving me their support.



Abdalla Mahmoud Tawfik

LIST OF CONTENTS

	Page
Acknowledgment	--
List of Abbreviations	i
List of Tables	iv
List of Figures	vi
Introduction	1
Aim of the Work	5
Review of Literature	6
Chapter 1: Hepatitis C virus	6
Chapter 2: Liver Cirrhosis	34
Chapter 3: Hepatocellular carcinoma (HCC)	58
Chapter 4: Fetuin-A	98
Patients and Methods	129
Results	133
Discussion	146
Summary	150
Recommendations	152
References	153
Arabic Summary	--

List of Abbreviations

A1AT	Alpha 1-antitrypsin
AFB1	Aflatoxins B1
AFP	Alpha Fetoprotein
ALT	Aspartate Transaminase
ALT	Alanin Trasferase
ApoA1	Apolipoprotein A1
APP	Acute Phase Proteins
AST	ASpartate Trasferase
AT-II	Angiotensin-II
CBC	Complete blood count
CF	Cystic Fibrosis
CP	Child Pugh classes
CPT	Child-Pugh Turcotte
CRP	C-reactive protein
CT	Computed Tomography
CVD	Cardiovascular Disease
D- Bil	Direct Bilirubin
ECs	Endothelial Cells
ELISA	Enzyme-linked immunosorbent assay
ESRD	End Stage Renal Disease
ETs	Endothelins
FMC	Fetuin- Mineral Complex
GGT	Gamma Glutamyl Transpeptidase
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HC	Healthy control
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C virus
HDL	High Density Lipoprotein
HE	Hepatic Encephalopathy
HGF	Hepatocyte Growth Factor
HH	Hereditary Hemochromatosis
HMW	High Molecular Weight
HPS	Hepato-pulmonary Syndrome

List of Abbreviations (Cont.)

HR	Heart rate
HRS	Hepatorenal Syndrome
HSCs	Hepatic stellate cells
HT1	Hereditary Tyrosinemia
IFN-γ	Gamma Interferon
IG	Immunoglobulin
IL	Interleukins
INR	International Normalisation Rate
IVC	Inferior Vena Cava
K	Potassium
LAK	Lymphokins Activating Killer cells
LC	Liver cirrhosis
LDL	Low-Density Lipoprotein
LPS	Lipopolysaccharide
MELD	Model for End-stage Liver Disease
MetS	Metabolic Syndrome
MMSE	Mini-Mental State Examination
MRI	Magnetic Resonance Imaging
Na	Sodium
NAFLD	Non Alcoholic Fatty Liver Disease
NASH	Nonalcoholic steatohepatitis
NO	Nitric Oxide
O.V	Esophageal Varices
OLT	Orthotopic Liver Transplantation
OV	Oesophageal Varices
PBC	Primary Biliary Cirrhosis
PDGF	Platelet Derived Growth Factor
PEI	Percutaneous Ethanol Injection
PH	Portal Hypertension
PHG	Portal Hypertensive Gastropathy
PHT	Portal Hypertension
PPH	Porto Pulmonary Hypertension
PSC	Primary Sclerosing Cholangitis
PT	Prothrombin Time

List of Abbreviations (Cont.)

PTT	Partial Thromboplastin time
PV	Portal Vein
RAAS	Renin-Angiotensin-Aldosterone System
RFA	Radiofrequency Ablation
SBP	Spontaneous Bacterial Peritonitis
T- Bil	Total Bilirubin
T- Prot	Total Protein
TACE	Transcatheter Arterial Chemoembolization
TGF	Transforming Growth Factor
TGF- α 1	Transforming growth factor α 1
TIPSS	Transjugular intrahepatic portosystemic shunt
TNF	Tumor Necrosing Factor
US	Abdominal ultrasound

LIST OF TABLES

Table No	Title	Page No
1	HCV Epidemiology in Egypt in 2013.	11
2	Indications for treatment of chronic hepatitis C in 2015: who should be treated and when?	26
3	Doses, medical forms and route of administration of antiviral agent.	27
4	Laennec scoring system for staging fibrosis in liver biopsy.	36
5	Child-Pugh Turcotte score.	45
6	Year survivals in liver cirrhosis classes using CPT	45
7	Prevention and treatment for complications of cirrhosis.	56
8	TNM Classification for Hepatocellular.	80
9	Anatomic stage/prognostic groups.	80
10	Cancer of the Liver Italian Program.	81
11	Effects of MELD scores and serum fetuin-A levels on the survival of patients with liver cirrhosis.	124
12	Comparison between the three groups using One-way ANOVA followed by pairwise comparisons.	131
13	year survivals in liver cirrhosis classes using CPT	131
14	Comparison between the three groups using One-way ANOVA followed by pairwise comparisons	134
15	Comparison between the three groups using pairwise comparisons.	135
16	Comparison between age of the three groups using One-way ANOVA followed by pairwise comparisons.	135
17	Comparison between age of the three groups using pairwise comparisons.	136
18	Gender distribution between the studied groups	136
19	Fetuin A and child score in the cirrhosis and HCC groups	137
20	Pearson correlation coefficients between Fetuin A and Alpha-fetoprotein in the three studied groups	137
21	Fetuin A with HCC number of lesions	138
22	Pearson correlation coefficients between Fetuin A and MELD, MELD % and the largest dimension of the tumor	138
23	Comparison between fetuin A in control vs cirrhosis ROC curve Fetuin A in Control vs. Cirrhosis Area under the ROC curve	139

Table No	Title	Page No
	(AUC)	
24	Comparison between Fetuin A in control vs HCC, ROC curve Fetuin A in Control vs HCC. Area under the ROC curve (AUC)	140
25	Comparison between Fetuin A in cirrhosis vs HCC ROC curve Fetuin A in cirrhosis vs HCC Area under the ROC curve (AUC)	141
26	Comparison between alpha-fetoprotein in control vs cirrhosis. ROC curve Alpha-fetoprotein in Control vs. Cirrhosis	142
27	Comparison between alpha-fetoprotein in control vs HCC. ROC curve Alpha-fetoprotein in Control vs HCC	143
28	Comparison between alpha-fetoprotein in cirrhosis vs HCC. ROC curve Alpha-fetoprotein in cirrhosis vs HCC	144
29	HCC cases with the cutoff point between Cirrhosis and HCC	145

LIST OF FIGURES

No	Title	Page
1	Countries Responsible for 80% of Global HCV Infection.	7
2	Viraemic HCV Prevalence by age and gender, 2008.	10
3	Mechanism of action of direct acting antivirals for Hepatitis C virus.	17
4	Relationship between portal hypertension, ascites and Hepatorenal syndrome through changes of plasma volume and impaired water excretion.	50
5	Patho-physiology of cirrhosis and HCC.	65
6	Histologic features of Hepatocellular carcinoma.	68
7	US showing Fat-containing HCC.	75
8	CT scan showing HCC.	76
9	MRI of a liver with hepatocellular carcinoma.	78
10	Staging and treatment according to the BCLC system	86
11	Radiofrequency Ablation technique.	88
12	CT of a large heterogeneous hepatocellular carcinoma treated with sorafenib.	89
13	Structure of fetuin-A.	101
14	Inhibitory effect of fetuin-A on ectopic calcification through formation of fetuin- mineral complex.	103
15	The molecular pathway linking fetuin-A, fatty liver and insulin resistance.	105
16	Increased stained glycosylated-fetuin-A in tumor tissue compared to non-tumor tissue by used immunohistochemical labeling.	127
17	Fetuin A level – mean and 95% confidence interval in the three studies groups.	135
18	Comparison between Fetuin A in control vs cirrhosis.	139